Remus Pharmaceuticals Ltd IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 184,200 (47%) | — | ₹2,264 Cr |
| NII (HNI) | — | 55,300 (14%) | — | ₹680 Cr |
| Retail | — | 129,000 (33%) | — | ₹1,585 Cr |
| Market Maker | — | 19,500 (5%) | — | ₹24 Cr |
| Σ Total | — | 388,000 (100%) | — | ₹47,685 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 100 | ₹122,900 |
| Retail (Max) | 13 | 1,300 | ₹1,597,700 |
| S-HNI (Min) | 14 | 1,400 | ₹1,720,600 |
| B-HNI (Min) | 67 | 6,700 | ₹8,234,300 |
Financial Statements Amount in ₹ Lakhs
| Metric | 31-Dec-22 | 31-Mar-22 | 31-Mar-21 |
|---|---|---|---|
| Revenue | 3,361 | 2,544 | 1,922 |
| Profit After Tax | 644 | 339 | 103 |
| Net Worth | 1,712 | 643 | 305 |
| Total Assets | 3,353 | 1,591 | 1,105 |
| Reserves & Surplus | 1,604 | 543 | 304 |
| Total Borrowing | 947 | 19 | 28 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- To Meet Working Capital Requirements – 30.30
- Funding investments for acquisitions and general corporate purposes – 16.38
- Public Issue Expenses – 1.00
Company Overview
Incorporated in 2015, Remus Pharmaceuticals Limited is engaged in the marketing and distributing of finished formulations of pharmaceutical drugs.
The product offerings of the company can be classified into two major categories:
- APIs: Active Pharmaceutical Ingredient (API) is the biologically active component of a drug product (tablet, capsule, cream, injectable) that produces the intended effects.
- Finished Pharmaceutical Formulations: Finished pharmaceutical formulations are therapeutic drugs available in different dosage forms.
The product portfolio consists of 429 products, as on January 31, 2023. They operate under different brand names across the globe. As on January 31, 2023, the company has 295 products registered in a total of 13 countries. As on January 31, 2023, a total of 134 ;products are under the process of registration in 16 countries.
As on January 31, 2023, Remus Pharmaceuticals had business-to-business supply agreements with 58 domestic distributors and 139 international distributors for distribution and/or contract manufacturing supply.
The company has cultivated strong and dependable customer relationships and its clients are spread in more than 20 countries. These clients range from Generic distributors, regional distributors, and Multinational distributors to Hospitals and Clinics.